An approach to evaluate the ability of rats to discriminate different levels of illumination in the plus maze test: Effects of scopolamine

Behavioural Brain Research

Volumn 180, Issue 1, 2007, Pages 86-94

  de Araújo Godinho, Marcos Aurélio ^a   Meneghini, Luana ^a   Lucinda, Aparecida Marcia ^a   Borges, Fábio Rodrigo Mesquita ^a   Sakae, Diana Yae ^a   Marino Neto, José ^a   Paschoalini, Marta Aparecida ^a   de Lima, Thereza Christina Monteiro ^a   Faria, Moacir Serralvo ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Anxiety; Brightness discrimination; Elevated plus maze; Illumination; Rat; Scopolamine; Side effects; Vision

Indexed keywords

ANXIOLYTIC AGENT; MIDAZOLAM; SCOPOLAMINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; EXPLORATORY BEHAVIOR; ILLUMINATION; LIGHT; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; RELIABILITY; TRANQUILIZING ACTIVITY; VALIDITY; VISUAL DISCRIMINATION; VISUAL SYSTEM;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; ASSOCIATION LEARNING; AVOIDANCE LEARNING; DISCRIMINATION LEARNING; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; LIGHTING; MALE; MAZE LEARNING; RATS; RATS, WISTAR; SCOPOLAMINE; STATISTICS, NONPARAMETRIC; VISION DISORDERS; VISUAL PERCEPTION;

EID: 34247486885     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2007.02.024     Document Type: Article

References (33)

1. Ahl A.S. The role of vibrissae in behavior: a status review. Vet Res Commun 10 (1986) 245-268
2. Albrechet-Souza L., Oliveira A.R., De Luca M.C.Z., Tomazini F.M., Santos N.R., and Brandão M.L. A comparative study with two types of elevated plus-maze (transparent vs. opaque walls) on the anxiolytic effects of midazolam, one-trial tolerance and fear-induced analgesia. Progr Neuro-Psychopharmacol Biol Psych 29 (2005) 571-579
3. Anglade F., Chapoutier G., and Galey D. Intraseptal injection of scopolamine increases the effect of the systemic diazepam on passive avoidance learning and emotionality in rats. Life Sci 64 (1999) 1553-1561
4. Anseloni V.Z., Motta V., Lima G., and Brandão M.L. Behavioral and pharmacological validation of the elevated plus maze constructed with transparent walls. Braz J Med Biol Res 28 (1995) 597-601
5. Bertoglio L.J., and Carobrez A.P. Scopolamine given pre-trial 1 prevents the one-trial tolerance phenomenon in the elevated plus-maze trial 2. Behav Pharmacol 15 (2004) 45-54
6. Calzavara M.B., Patti C.L., Lopez G.B., Abilio V.C., Silva R.H., and Frussa-Filho R. Role of learning of open arm avoidance in the phenomenon of one-trial tolerance to the anxiolytic effect of chlordiazepoxide in mice. Life Sci 76 (2005) 2235-2246
7. Cardenas F., Lamprea M.R., and Morato S. Vibrissal sense is not the main sensory modality in rat exploratory behaviour in the elevated plus-maze. Behav Brain Res 122 (2001) 169-174
8. Curran H.V., Schifano F., and Lader M. Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood. Psychopharmacology (Berl) 103 (1991) 83-90
9. De-Mello N., and Carobrez A.P. Elevated T-maze as an animal model of memory: effects of scopolamine. Behav Pharmacol 13 (2002) 139-148
10. Dere E., Topic B., De Souza Silva M., Srejic M., Frisch C., Buddenberg T., and Huston J.P. The graded anxiety test: a novel test of murine unconditioned anxiety based on the principles of the elevated plus-maze and light-dark test. J Neurosci Methods 122 (2002) 65-73
11. File S.E. Behavioural detection of anxiolytic action. In: Elliott J.M., Heal D.J., and Marsden C.A. (Eds). Experimental approaches to anxiety and depression (1992), John Willey & Sons, New York 25-44
12. Furey M.L., and Drevets W.C. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 63 (2006) 1121-1129
13. Gold P.E. Acetylcholine modulation of neural systems involved in learning and memory. Neurobiol Learn Mem 80 (2003) 194-210
14. Griebel G., Moreau J.L., Jenck F., Martin J.R., and Misslin R. Some critical determinants of the behaviour of rats in the elevated plus-maze. Behav Proc 29 (1993) 37-48
15. Grossen N.E., and Kelley M.J. Species-specific behavior and acquisition of avoidance behavior in rats. J Comp Physiol Psychol 81 (1972) 307-310
16. Handley S.L., and Mithani S. Effects of α2-adrenoceptor agonists and antagonists in a maze exploration model of fear-motivated behaviour. N S Arch Pharmacol 327 (1984) 1-5
17. Martínez J.C., Cardenas F., Lamprea M., and Morato S. The role of vision and proprioception in the aversion of rats to the open arms of an elevated plus-maze. Behav Proc 60 (2002) 15-26
18. Nobili L., and Sannita W.G. Cholinergic modulation, visual function and Alzheimeŕs dementia. Vision Res 37 (1997) 35559-43571
19. Ottoni E.B. EthoLog 2.2: a tool for the transcription and timing of behaviour observation sessions. Behav Res Methods Instrum Comput 32 (2000) 446-449
20. Pellow S., Chopin P., File S.E., and Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14 (1985) 149-167
21. Pepeu G., and Giovannini M.G. Changes in acetylcholine extracellular levels during cognitive processes. Learn Mem 11 (2004) 21-27
22. Pereira L.O., Da Cunha I.C., Marino Neto J., Paschoalini M.A., and Faria M.S. The gradient of luminosity between open/enclosed arms, and not the absolute level of Lux, predicts the behaviour of rats in the plus maze. Behav Brain Res 159 (2005) 55-61
23. Robinson L., Harban D., and Riedel G. Visual acuity in the water maze: sensitivity to muscarinic receptor blockade in rats and mice. Behav Brain Res 151 (2004) 277-286
24. Rodgers R.J., and Cole J.C. The elevated plus-maze: pharmacology, methodology and ethology. In: Cooper S.J., and Hendrie C.A. (Eds). Ethology and psychopharmacology (1994), John Wiley & Sons Ltd, Chichester 9-44
25. Rodgers R.J., and Cole J.C. Effects of scopolamine and its quaternary analogue in the murine elevated plus-maze test of anxiety. Behav Pharmacol 6 (1995) 283-289
26. Rodgers R.J., Johnson N.J., Cole J.C., Dewar C.V., Kidd G.R., and Kimpson P.H. Plus-maze retest profile in mice: importance of initial stages of trial 1 and response to post-trail cholinergic receptor blockade. Pharmacol Biochem Behav 54 (1996) 41-50
27. Shimada T., Matsumoto K., Osanai M., Matsuda H., Terasawa K., and Watanabe H. The modified light/dark transition test in mice: evaluation of classic and putative anxiolytic and anxiogenic drugs. Gen Pharmacol 26 (1995) 205-210
28. Simon P., Dupuis R., and Costentin J. Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions. Behav Brain Res 61 (1994) 59-64
29. Smythe J.W., Murphy D., Bhatnagar S., Timothy C., and Costall B. Muscarinic antagonists are anxiogenic in rats tested in the black-white box. Pharmacol Biochem Behav 54 (1996) 57-63
30. Trei D. A comparison of anxiolytic and nonanxiolytic agents in the shock-probe/burying test for anxiolytics. Pharmacol Biochem Behav 36 (1990) 203-205
31. Treit D., Menard J., and Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 44 (1993) 463-469
32. Umezu T. Effects of psychoactive drugs in the Vogel conflict test in mice. JPN J Pharmacol 80 (1999) 111-118
33. Wallace D.G., Gorny B., and Whishaw I.Q. Rats can track odours, other rats, and themselves: implications for the study of spatial behaviour. Behav Brain Res 131 (2002) 185-192